CPCB-RPE1 Implant
Advanced Dry Age-Related Macular Degeneration (Geographic Atrophy)
Key Facts
About Regenerative Patch Technologies
Regenerative Patch Technologies is a private, clinical-stage biotech focused on a novel implantable therapy for geographic atrophy, the advanced form of dry age-related macular degeneration (AMD). Its core technology, the CPCB-RPE1 implant, combines stem cell-derived RPE cells on a synthetic membrane to replace degenerated eye structures. The company has completed a Phase I/IIa trial with encouraging vision preservation/gain signals and is now enrolling patients in a Phase IIb trial, supported by significant non-dilutive funding from CIRM and foundations. RPT represents a potentially transformative, one-time surgical alternative to current chronic injection therapies that only slow disease progression.
View full company profile